Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 4Colorectal Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraganglioma, Extra-Adrenal 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Osteosarcoma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Lymphoma 1Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma 1Gynecological Cancer 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Esophageal Squamous Cell Carcinoma 1Digestive System Diseases 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

Rituximab 259Cyclophosphamide 238Etoposide 114Prednisone 97Vincristine 96Doxorubicin 96Peripheral Blood Stem Cell Transplantation 95fludarabine phosphate 87Filgrastim 80Cytarabine 61Lenalidomide 60Mycophenolic Acid 59Melphalan 59Radiotherapy 58Busulfan 52Cyclosporine 50Carmustine 49Whole-Body Irradiation 48Tacrolimus 46Methotrexate 42Antilymphocyte Serum 38Gemcitabine 33Ifosfamide 32Carboplatin 32fludarabine 31Dexamethasone 31polatuzumab vedotin 29Granulocyte Colony-Stimulating Factor 29CT-P10 28Methylprednisolone 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Large B-Cell, Diffuse × penpulimab × Clear all
NCT06516978 2024-07-24

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
528 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
54 enrolled
Lymphoid

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡